<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "inFLIXimab inj VIAL">
<dose><value>5</value>
<value>10</value>
<value>3</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>inFLIXimab inj VIAL</value>
</drugname><strength><value>100 mg</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value>Administer dose intravenously over 2 hours.</value>
</instruction><volume></volume><units><value>mg/kg</value>
</units><additionalnotes><value>Crohn's Disease / Fistulizing Crohn's Disease: followed by additional doses at 2 and 6 weeks after initial dose, then every 8 weeks thereafter. Patients identified as carriers of Hepatitis B virus should be monitored for signs/symptoms of relapse of HBV infection throughout therapy and several months following termination of therapy.</value>
<value>Fistulizing Crohn's Disease in patients no longer responsing to 5 mg/kg treatment. Patients identified as carriers of Hepatitis B virus should be monitored for signs/symptoms of relapse of HBV infection throughout therapy and several months following termination of therapy.</value>
<value>Rheumatoid Arthritis: followed by additional doses at 2 and 6 weeks after initial dose, then every 8 weeks thereafter. Patients identified as carriers of Hepatitis B virus should be monitored for signs/symptoms of relapse of HBV infection throughout therapy and several months following termination of therapy.</value>
</additionalnotes><population></population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3608</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary with Restrictions.</value>
</ahsformularystatus><ahfsname><value>Disease-modifying Antirheumatic Agents</value>
</ahfsname><highalert></highalert><maximumprndose></maximumprndose><din><value>2244016</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>